Compare WAY & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | RYTM |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.4B |
| IPO Year | 2024 | 2017 |
| Metric | WAY | RYTM |
|---|---|---|
| Price | $32.84 | $111.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $46.87 | ★ $127.31 |
| AVG Volume (30 Days) | ★ 2.5M | 1.0M |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,039,842,000.00 | $174,334,000.00 |
| Revenue This Year | $16.37 | $47.34 |
| Revenue Next Year | $16.85 | $57.18 |
| P/E Ratio | $52.80 | ★ N/A |
| Revenue Growth | 14.76 | ★ 54.92 |
| 52 Week Low | $29.40 | $45.91 |
| 52 Week High | $48.11 | $122.20 |
| Indicator | WAY | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 57.05 |
| Support Level | $32.10 | $109.99 |
| Resistance Level | $33.34 | $115.05 |
| Average True Range (ATR) | 1.34 | 5.20 |
| MACD | -0.00 | 0.60 |
| Stochastic Oscillator | 50.00 | 53.93 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.